首页> 外文期刊>The New England journal of medicine >Detection of APC mutations in fecal DNA from patients with colorectal tumors.
【24h】

Detection of APC mutations in fecal DNA from patients with colorectal tumors.

机译:检测大肠肿瘤患者粪便DNA中的APC突变。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Noninvasive methods for detecting colorectal tumors have the potential to reduce morbidity and mortality from this disease. The mutations in the adenomatous polyposis coli (APC) gene that initiate colorectal tumors theoretically provide an optimal marker for detecting colorectal tumors. The purpose of our study was to determine the feasibility of detecting APC mutations in fecal DNA with the use of newly developed methods. METHODS: We purified DNA from routinely collected stool samples and screened for APC mutations with the use of a novel approach called digital protein truncation. Many different mutations could potentially be identified in a sensitive and specific manner with this technique. RESULTS: Stool samples from 28 patients with nonmetastatic colorectal cancers, 18 patients with adenomas that were at least 1 cm in diameter, and 28 control patients without neoplastic disease were studied. APC mutations were identified in 26 of the 46 patients with neoplasia (57 percent; 95 percent confidence interval, 41 to 71 percent) and in none of the 28 control patients (0 percent; 95 percent confidence interval, 0 to 12 percent; P<0.001). In the patients with positive tests, mutant APC genes made up 0.4 to 14.1 percent of all APC genes in the stool. CONCLUSIONS: APC mutations can be detected in fecal DNA from patients with relatively early colorectal tumors. This feasibility study suggests a new approach for the early detection of colorectal neoplasms.
机译:背景:用于检测结直肠肿瘤的非侵入性方法具有降低该疾病的发病率和死亡率的潜力。理论上,引发大肠肿瘤的腺瘤性息肉病(APC)基因突变为检测大肠肿瘤提供了最佳标记。我们研究的目的是确定使用新开发的方法检测粪便DNA中APC突变的可行性。方法:我们从常规采集的粪便样本中纯化了DNA,并使用一种称为数字蛋白截断的新方法筛选了APC突变。使用该技术可以潜在地以敏感和特定的方式识别许多不同的突变。结果:研究了来自28例非转移性结直肠癌患者,18例直径至少1 cm的腺瘤患者和28例无肿瘤性疾病的对照患者的粪便样本。在46例瘤形成患者中有26例(57%; 95%置信区间为41%至71%)中发现了APC突变,在28例对照患者中均未发现APC突变(0%; 95%可信区间为0%至12%; P < 0.001)。在阳性试验的患者中,突变的APC基因占粪便中所有APC基因的0.4%至14.1%。结论:相对较早的大肠肿瘤患者,粪便DNA中可检测到APC突变。这项可行性研究为大肠肿瘤的早期发现提出了一种新方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号